Erick Lucera - Apr 3, 2023 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Role
Director
Signature
/s/ Erick Lucera
Stock symbol
SABS
Transactions as of
Apr 3, 2023
Transactions value $
$0
Form type
4
Date filed
4/5/2023, 05:01 PM
Previous filing
Mar 31, 2023
Next filing
May 18, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SABS Employee Stock Option (right to buy) Award $0 +25K $0.00 25K Apr 3, 2023 Common Stock 25K $0.47 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan.
F2 The shares underlying the option vest over a three-year period, vesting 1/36 monthly beginning with the month following the Reporting Person's commencement of service as a director (April 3, 2023). This represents the initial grant to the Reporting Person as a member of the Board of Directors.